Minimal residual diseases detection in childhood cancers

Project leader: Prof Ellen van der Schoot MD PhD

The prognosis of cancers in childhood is often better than in adults, but yet many children do not survive. To recognize children who might benefit from other therapeutic strategies, in collaboration with GA Tytgat, HN Caron and R Versteeg (AMC/ EKZ, Amsterdam), V de Haas (SKION), JJM van Dongen and VHJ van der Velden (Erasmus MC), we develop and evaluate assays for the detection of minimal residual disease in childhood cancers. We demonstrated that hyper-methylated RASSF1a can be used as a DNA marker for the detection of minimal residual disease for neuroblastoma.

Key publication

Last edited on: 27 September 2012